337 related articles for article (PubMed ID: 22966907)
1. Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis.
Gupta A; Cao W; Chellaiah MA
Mol Cancer; 2012 Sep; 11():66. PubMed ID: 22966907
[TBL] [Abstract][Full Text] [Related]
2. DU145 human prostate cancer cells express functional receptor activator of NFkappaB: new insights in the prostate cancer bone metastasis process.
Mori K; Le Goff B; Charrier C; Battaglia S; Heymann D; Rédini F
Bone; 2007 Apr; 40(4):981-90. PubMed ID: 17196895
[TBL] [Abstract][Full Text] [Related]
3. Characterization of CD44 intracellular domain interaction with RUNX2 in PC3 human prostate cancer cells.
Senbanjo LT; AlJohani H; Majumdar S; Chellaiah MA
Cell Commun Signal; 2019 Jul; 17(1):80. PubMed ID: 31331331
[TBL] [Abstract][Full Text] [Related]
4. Mechanisms of osteopontin and CD44 as metastatic principles in prostate cancer cells.
Desai B; Rogers MJ; Chellaiah MA
Mol Cancer; 2007 Mar; 6():18. PubMed ID: 17343740
[TBL] [Abstract][Full Text] [Related]
5. Butein, a tetrahydroxychalcone, suppresses cancer-induced osteoclastogenesis through inhibition of receptor activator of nuclear factor-kappaB ligand signaling.
Sung B; Cho SG; Liu M; Aggarwal BB
Int J Cancer; 2011 Nov; 129(9):2062-72. PubMed ID: 21170936
[TBL] [Abstract][Full Text] [Related]
6. Induction of osteoclast differentiation by Runx2 through receptor activator of nuclear factor-kappa B ligand (RANKL) and osteoprotegerin regulation and partial rescue of osteoclastogenesis in Runx2-/- mice by RANKL transgene.
Enomoto H; Shiojiri S; Hoshi K; Furuichi T; Fukuyama R; Yoshida CA; Kanatani N; Nakamura R; Mizuno A; Zanma A; Yano K; Yasuda H; Higashio K; Takada K; Komori T
J Biol Chem; 2003 Jun; 278(26):23971-7. PubMed ID: 12697767
[TBL] [Abstract][Full Text] [Related]
7. Murine and chicken chondrocytes regulate osteoclastogenesis by producing RANKL in response to BMP2.
Usui M; Xing L; Drissi H; Zuscik M; O'Keefe R; Chen D; Boyce BF
J Bone Miner Res; 2008 Mar; 23(3):314-25. PubMed ID: 17967138
[TBL] [Abstract][Full Text] [Related]
8. A CTGF-RUNX2-RANKL Axis in Breast and Prostate Cancer Cells Promotes Tumor Progression in Bone.
Kim B; Kim H; Jung S; Moon A; Noh DY; Lee ZH; Kim HJ; Kim HH
J Bone Miner Res; 2020 Jan; 35(1):155-166. PubMed ID: 31505052
[TBL] [Abstract][Full Text] [Related]
9. Estrogens antagonize RUNX2-mediated osteoblast-driven osteoclastogenesis through regulating RANKL membrane association.
Martin A; Xiong J; Koromila T; Ji JS; Chang S; Song YS; Miller JL; Han CY; Kostenuik P; Krum SA; Chimge NO; Gabet Y; Frenkel B
Bone; 2015 Jun; 75():96-104. PubMed ID: 25701138
[TBL] [Abstract][Full Text] [Related]
10. RANK- and c-Met-mediated signal network promotes prostate cancer metastatic colonization.
Chu GC; Zhau HE; Wang R; Rogatko A; Feng X; Zayzafoon M; Liu Y; Farach-Carson MC; You S; Kim J; Freeman MR; Chung LW
Endocr Relat Cancer; 2014 Apr; 21(2):311-26. PubMed ID: 24478054
[TBL] [Abstract][Full Text] [Related]
11. RANKL acts directly on RANK-expressing prostate tumor cells and mediates migration and expression of tumor metastasis genes.
Armstrong AP; Miller RE; Jones JC; Zhang J; Keller ET; Dougall WC
Prostate; 2008 Jan; 68(1):92-104. PubMed ID: 18008334
[TBL] [Abstract][Full Text] [Related]
12. Early estrogen-induced gene 1, a novel RANK signaling component, is essential for osteoclastogenesis.
Choi HK; Kang HR; Jung E; Kim TE; Lin JJ; Lee SY
Cell Res; 2013 Apr; 23(4):524-36. PubMed ID: 23478294
[TBL] [Abstract][Full Text] [Related]
13. Association of sustained ERK activity with integrin beta3 induction during receptor activator of nuclear factor kappaB ligand (RANKL)-directed osteoclast differentiation.
Kim HH; Chung WJ; Lee SW; Chung PJ; You JW; Kwon HJ; Tanaka S; Lee ZH
Exp Cell Res; 2003 Oct; 289(2):368-77. PubMed ID: 14499638
[TBL] [Abstract][Full Text] [Related]
14. Macrolactin F inhibits RANKL-mediated osteoclastogenesis by suppressing Akt, MAPK and NFATc1 pathways and promotes osteoblastogenesis through a BMP-2/smad/Akt/Runx2 signaling pathway.
Li L; Sapkota M; Gao M; Choi H; Soh Y
Eur J Pharmacol; 2017 Nov; 815():202-209. PubMed ID: 28919027
[TBL] [Abstract][Full Text] [Related]
15. Mechanical strain-mediated reduction in RANKL expression is associated with RUNX2 and BRD2.
Galea GL; Paradise CR; Meakin LB; Camilleri ET; Taipaleenmaki H; Stein GS; Lanyon LE; Price JS; van Wijnen AJ; Dudakovic A
Gene; 2020 Dec; 763S():100027. PubMed ID: 34493364
[TBL] [Abstract][Full Text] [Related]
16. Coupling of bone resorption and formation by RANKL reverse signalling.
Ikebuchi Y; Aoki S; Honma M; Hayashi M; Sugamori Y; Khan M; Kariya Y; Kato G; Tabata Y; Penninger JM; Udagawa N; Aoki K; Suzuki H
Nature; 2018 Sep; 561(7722):195-200. PubMed ID: 30185903
[TBL] [Abstract][Full Text] [Related]
17. Expression of the IL-11 Gene in Metastatic Cells Is Supported by Runx2-Smad and Runx2-cJun Complexes Induced by TGFβ1.
Zhang X; Wu H; Dobson JR; Browne G; Hong D; Akech J; Languino LR; Stein GS; Lian JB
J Cell Biochem; 2015 Sep; 116(9):2098-108. PubMed ID: 25808168
[TBL] [Abstract][Full Text] [Related]
18. Triptolide, a diterpene, inhibits osteoclastogenesis, induced by RANKL signaling and human cancer cells.
Park B
Biochimie; 2014 Oct; 105():129-36. PubMed ID: 25047443
[TBL] [Abstract][Full Text] [Related]
19. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis.
Zhang Z; Jimi E; Bothwell AL
J Immunol; 2003 Oct; 171(7):3620-6. PubMed ID: 14500659
[TBL] [Abstract][Full Text] [Related]
20. Delineating role of NF-κB and interacting cytokines during prostate cancer-induced osteoclastogenesis.
Jadli M; Thakur K; Aggarwal N; Chhokar A; Bibban R; Singh T; Bhat A; Bharti AC
J Cell Biochem; 2021 Feb; 122(2):259-276. PubMed ID: 33053226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
